JAKAVI (ruxolitinib) | HCP
JAKAVI (ruxolitinib) for the treatment of myelofibrosis and for the treatment of polycythaemia vera in patients resistant to or intolerant of hydroxyurea.
Sprache: Englisch
Working together, we can reimagine medicine to improve and extend people's lives.
MPN Tracker for Polycythemia Vera, Myelofibrosis & Essential Thrombocythemia. MPN Tracker helps ID matching diagnosis while tracking symptoms and conditions.
Unipharma, a Swiss company in Lugano, with heritage know-how in the distribution of medicines that are not marketed or temporarily unavailable.
Patienten-Reportagen aus allen Bereichen der Gesundheit